

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria. Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/663,050	09/15/2003	John C. Ulicny	GP-301599	1997
7590 07/15/2004			EXAMINER	
CARY W. BROOKS			KOSLOW, CAROL M	
General Motors Corporation Mail Code 482-C23-B21		ART UNIT	PAPER NUMBER	
P.O. Box 300			1755	
Detroit, MI 48265-3000			DATE MAIL ED. 07/15/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
	10/663,050	ULICNY ET AL.	
Office Action Summary	Examiner	Art Unit	
	C. Melissa Koslow	1755	
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address	
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	66(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days fill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).	
Status			
1) Responsive to communication(s) filed on	_• • •		
2a) This action is FINAL . 2b) ⊠ This	action is non-final.		
3) Since this application is in condition for allowar			
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	63 O.G. 213.	
Disposition of Claims			
4) Claim(s) is/are pending in the applicatio	n.		
4a) Of the above claim(s) is/are withdraw			
5) Claim(s) is/are allowed.			
6)⊠ Claim(s) <u>1-22</u> is/are rejected.		•	
7) Claim(s) is/are objected to.			
8) Claim(s) are subject to restriction and/or	r election requirement.		
Application Papers		•	
9) The specification is objected to by the Examine	r		
10)⊠ The drawing(s) filed on 15 September 2003 is/a	are: a)⊠ accepted or b)□ objec	ted to by the Examiner.	
Applicant may not request that any objection to the	drawing(s) be held in abeyance. See	e 37 CFR 1.85(a).	
Replacement drawing sheet(s) including the correct	·		
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.	
Priority under 35 U.S.C. § 119			
12)☐ Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 119(a))-(d) or (f).	
a) All b) Some * c) None of:			
1. Certified copies of the priority document	s have been received.		
Certified copies of the priority documents	s have been received in Applicati	on No	
Copies of the certified copies of the prior	rity documents have been receive	ed in this National Stage	
application from the International Bureau			
* See the attached detailed Office action for a list	of the certified copies not receive	ed. ,	
American and a			
Attachment(s) 1) Notice of References Cited (PTO-892)	4) Interview Summary	(PTO-413)	
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	ate	
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	5) Notice of Informal P 6) Other:	atent Application (PTO-152)	

Application/Control Number: 10/663,050

Art Unit: 1755

Applicant has complied with the conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 120.

The disclosure is objected to because of the following informalities: The status of application 09/923,303 needs to be updated. Appropriate correction is required.

The listing of references in the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609 A(1) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892, they have not been considered.

Page 9, lines 6 defines the term "about 300" as meaning "less than 300". Accordingly, "about 300" in claim 15 means "less than 300".

A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process ... may obtain a patent therefor ..." (Emphasis added). Thus, the term "same invention," in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957); and *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the conflicting claims so they are no longer coextensive in scope. The filing of a terminal disclaimer <u>cannot</u> overcome a double patenting rejection based upon 35 U.S.C. 101.

Claims 1-19 are provisionally rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 1-19 of copending Application No. 10/462,482. This is a provisional double patenting rejection since the conflicting claims have not in fact been patented.

Application/Control Number: 10/663,050

Art Unit: 1755

Claims 1-19 of this application conflict with claims 1-19 of Application No. 10/462,482.

37 CFR 1.78(b) provides that when two or more applications filed by the same applicant contain conflicting claims, elimination of such claims from all but one application may be required in the absence of good and sufficient reason for their retention during pendency in more than one application. Applicant is required to either cancel the conflicting claims from all but one application or maintain a clear line of demarcation between the applications. See MPEP § 822.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970), and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 20-22 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1, 9, 10, 13, 15, 16 and 19 of copending Application No. 10/462,482 in view of U.S. patents 6,395,193 and 3,615,565.

Claims 1, 9, 10, 13, 15, 16 and 19 of copending Application No. 10/462,482 differ from the compositions in claims 20-22 in that they do not teach the thiophosphate is zinc dibutylphosphorodithioate. U.S. patent 6,395,193 teaches zinc dialkyl dithiophosphates are known to be used as antioxidants in magnetorheological fluids and U.S. patent 3,615,565 teaches zinc dibutylphosphorodithioate is a known antioxidant. It is known that zinc

Application/Control Number: 10/663,050

Art Unit: 1755

dibutylphosphorodithioate is a species of zinc dialkyl dithiophosphate. One of ordinary skill in the art would have found it obvious to use zinc dibutylphosphorodithioate as the zinc dialkyl dithiophosphate taught in copending Application No. 10/462,482 when the zinc dialkyl dithiophosphate is used as an antioxidant in the fluid.

This is a provisional obviousness-type double patenting rejection.

U.S. Patents 5,900,184; 5,683,615 and 6,395,193 are made of record and not relied upon is considered pertinent to applicant's disclosure. These patents teach magnetorheological fluids similar to those claimed, but they do not teach or suggest the claimed compositions.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Melissa Koslow whose telephone number is (571) 272-1371. The examiner can normally be reached on Monday-Friday from 8:00 AM to 3:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mark Bell, can be reached at (571) 272-1362.

The fax number for all official communications is (703) 872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

cmk July 13, 2004 C. Melissa Koslow Primary Examiner Tech. Center 1700